BiotechTV - News Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
Jan 28, 2026
Richard Miller, Co-founder and CEO of Corvus Pharmaceuticals, leads clinical development of the ITK inhibitor soquelitinib. He discusses data consistency and a novel mechanism. He talks about durability and possible immune reset. He outlines intermittent and once-daily dosing plans, timing for 90‑day results, biomarkers, trial diversity, and plans to expand ITK into oncology and rare diseases.
AI Snips
Chapters
Transcript
Episode notes
ITK Proven As A Novel Therapeutic Target
- Corvus validated ITK as a novel, clinically meaningful target for inflammatory disease.
- Richard Miller positions soquelitinib as a pioneering, specific ITK inhibitor with consistent safety and efficacy.
Durable Effects After Short Drug Exposure
- Soquelitinib shows prolonged clinical effects after the drug clears from the body in hours.
- Miller calls this durability potentially revolutionary and a possible route toward disease modification.
Plan Trials For Longer Follow-Up
- Design trials with longer follow-up to capture durable responses; Corvus extended follow-up from 30 to 90 days.
- Anticipate intermittent dosing regimens rather than continuous lifelong therapy if safety and durability persist.